Cytokeratin-based CTC counting unrelated to clinical follow up

• Published in: Journal of thoracic disease 2013-10, Vol.5 (5), p.593-599
• Main Authors: Chinen, Ludmilla Thomé Domingos, de Carvalho, Fernanda Machado, Rocha, Bruna Maria Malagoli, Aguiar, Caroline Motta, Abdallah, Emne Ali, Campanha, Daniel, Mingues, Natália Breve, de Oliveira, Thiago Bueno, Maciel, Macello Sampaio, Cervantes, Gustavo Marchioro, Dettino, Aldo L A, Soares, Fernando Augusto, Paterlini-Bréchot, Patrizia, Fanelli, Marcello Ferretti
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2072-1439; 2077-6624
• DOI: 10.3978/j.issn.2072-1439.2013.09.18

Circulating tumor cells (CTCs) have been reported to be a relevant prognostic biomarker in metastatic patients. However, their clinical use and impact is still under debate. We have thus comparatively and kinetically assessed two CTC detection methods according to the patient's clinical follow up. CTC counting and characterization were repeatedly performed during follow up in a patient with metastatic undifferentiated non-small cell lung cancer by using cytokeratin (CK)-dependent immunomagnetic separation (Miltenyi) and CK-independent, size-based isolation [isolation by size of tumor cells (ISET)] (Rarecells). Comparison between the two methods showed a parallel increase of CTC detected by ISET and worsening of the clinical status, while CK-dependent CTC numbers were decreasing, misleadingly suggesting a response to treatment. ISET results were in agreement with the clinical follow up showing Circulating tumor microemboli (CTM) and CTC expressing a mesenchymal marker with absence of epithelial markers. This case report study shows the interest of a comparative and kinetic analysis of different methods for CTCs detection combined with their evaluation according to the clinical follow up. Our results should open up an area for future research and validation in larger clinical cohorts.